GLP-1 drugs like semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) have greatly changed the treatment of obesity and type 2 diabetes for the better. Plenty of adults in the U.S. have taken or are currently taking a GLP-1. And increasingly, so are teens and young children, too.
A study last week, for instance, concluded that while GLP-1 use overall remains rare in young children, it has significantly increased over time. Between 2019 and 2026, the researchers found, 0.6% of children ages 8 to 11 with obesity but without diabetes had been prescribed an off-label GLP-1, while the annual percentage of such children…
Read the full article at GIZMODO.COM




